Skin aging and tissue damage stem from a slow, steady decline in cellular activity. Over time, the structural scaffold holding everything together degrades. Fibroblasts slow down, collagen fibers fragment, and the skin loses its ability to repair itself after inflammation or trauma. Traditional cosmetic approaches often focus on surface hydration or temporary volume replacement. Newer biological strategies aim deeper: they target the underlying machinery responsible for tissue repair.

Polynucleotide therapy represents a shift toward genuine biological restoration. Rather than merely occupying space beneath the epidermis, these long-chain nucleotide polymers trigger specific signaling pathways that stimulate cell proliferation, promote angiogenesis, and reduce chronic inflammation. The biological mechanisms driving this technology explain why it has become such a compelling option for structural skin regeneration.

The Molecular Mechanism of Action

Polynucleotide injections utilize long-chain polymers composed of deoxyribonucleotide units. These molecules are typically derived from purified salmon-derived DNA fragments. The specific molecular weight and purifications ensure high biocompatibility with human tissue, reducing the likelihood of adverse immune responses while maximizing biological activity.

Once introduced into the dermis, these nucleotide chains break down into smaller nucleosides and free nucleotides. This gradual degradation fuels cellular repair through two primary pathways.

The primary mechanism involves activation of the adenosine A2A receptor. Nucleotides derived from PDRN (polydeoxyribonucleotide) bind to these receptors on the surface of various cell types, including fibroblasts and endothelial cells. Receptor activation triggers a cascade of intracellular events:

• Downregulation of pro-inflammatory cytokines, including TNF-alpha and IL-6.
• Upregulation of anti-inflammatory mediators like IL-10.
• Stimulation of vascular endothelial growth factor (VEGF), which initiates angiogenesis.
• Acceleration of cell recruitment and matrix assembly at sites of tissue damage.

The secondary path involves the nucleotide salvage pathway. Cells undergoing rapid repair or division require substantial amounts of purines and pyrimidines to synthesize new nucleic acids. Constructing these molecules from scratch demands significant energy. By providing readily available bases and nucleosides directly to the extracellular environment, polynucleotides save cells critical metabolic energy. Fibroblasts can allocate more resources toward matrix synthesis and structural restoration.

Cellular Repair and Extracellular Matrix Degradation

The extracellular matrix consists of a dense network of collagen, elastin, glycosaminoglycans, and structural glycoproteins. Fibroblasts maintain this complex structure. As skin ages, exposure to ultraviolet radiation and oxidative stress causes structural collapse. Collagen synthesis declines, while matrix metalloproteinases (MMP) actively degrade existing structural fibers.

Laboratory models show that exposure to purified nucleotides reverses this trajectory. When human dermal fibroblasts interact with polynucleotides, cell proliferation increases significantly. A 2014 study published in the Journal of Dermatological Science demonstrated that PDRN exposure increased human fibroblast proliferation in a dose-dependent manner while simultaneously accelerating extracellular matrix regeneration.

This cellular activation leads directly to increased collagen synthesis. Type I and Type III collagen production rises, alongside boosted synthesis of endogenous hyaluronic acid. Rather than introducing artificial volume, the tissue builds a fresh, dense structural network from within. Over time, this biological activity manifests as measurable improvements in dermal thickness and elasticity.

Clinical Applications in Advanced Skin Repair

Given their ability to alter tissue behavior at the molecular level, polynucleotides find applications across several complex dermatological conditions. Their regenerative profile makes them suitable for areas where thin skin or delicate underlying structures make traditional fillers impractical.

Treating Periorbital Skin

The skin around the eyes is exceptionally thin, making it vulnerable to early structural breakdown, vascular pooling, and fine wrinkling. Traditional hyaluronic acid fillers in this zone risk the Tyndall effect or persistent lymphatic edema.

Polynucleotide therapy offers a distinct mechanism here. By stimulating microcirculation through localized angiogenesis and promoting fibroblast activity, treatments improve skin density without causing swelling or fluid retention. Periorbital skin undergoes visible structural tightening as new collagen fibers stabilize the dermis.

Scar Revision and Acne Scars

Atrophic scarring resulting from severe acne represents a persistent challenge in dermatology. Loss of tissue integrity creates persistent indentations that resist topical treatments.

Polynucleotide injections help remodel fibrotic scar tissue. Intradermal microinjection deposits the active nucleotides directly into the scarred dermal layer. The resulting activation of the adenosine A2A receptor limits the prolonged inflammatory response typical of abnormal healing. Fibroblasts produce fresh, orderly collagen bundles, filling deep defects over sequential treatment sessions. Clinical evaluations of acne scars show noticeable texture normalization as healthy tissue replaces dense, disorganized scar fibers.

Evaluating Rejuran Formulations

Among the various options available in aesthetics, Rejuran has established itself as a benchmark for salmon-derived PDRN technology. Formulated specifically to harness purified salmon-derived DNA fragments, Rejuran focuses on restoring compromised dermal architecture through targeted bio-revitalization. Medical professionals often choose to shop Rejuran from a professional supplier to ensure product authenticity and consistent molecular quality for their clinical protocols. Rejuran works by introducing these highly biocompatible polynucleotide chains into damaged skin layers, where they gradually release nucleotides over time. Because Rejuran focuses on cellular renewal rather than immediate cross-linked volume filling, it addresses underlying tissue health directly.

Beyond basic skin maintenance, Rejuran is frequently utilized in specialized protocols targeting scar revision, deep wrinkles, and overall structural remodeling. Clinical evaluations consistently note that Rejuran improves overall skin texture by stimulating biological tissue repair. Practitioners often integrate Rejuran into complex treatment programs alongside energy-based devices to amplify healing responses.

Practical Administration and Protocol Standards

Achieving optimal results with polynucleotides depends heavily on precise delivery techniques. Because the goal is to interact directly with the dermal fibroblast population, placement must be accurate.

Practitioners typically use intradermal microinjection techniques. Micro-droplets of the solution are placed into the papillary or upper reticular dermis using thin-gauge needles or mesotherapy devices. Proper injection depth prevents waste, minimizes local bruising, and ensures proximity to target receptors.

Treatment schedules generally call for an initial series of three to four sessions spaced two to four weeks apart. This setup provides continuous cellular stimulation during the initial repair phase. Results develop progressively:

• Days 1 to 7: Initial cellular response, reduction in localized tissue inflammation, and early hydration changes.
• Weeks 2 to 4: Peak fibroblast proliferation and initiation of new collagen synthesis.
• Months 1 to 3: Progressive structural remodeling, measurable improvements in dermal thickness and elasticity, and tissue restructuring.

Follow-up maintenance treatments every six to twelve months help sustain the synthetic activity of the dermal fibroblast population.

Comparative Benefits in Regenerative Aesthetics

The rise of polynucleotide therapy reflects a broader movement toward regenerative treatments. Comparing these biologic agents to established modalities highlights their unique place in clinical practice.

Cross-linked hyaluronic acid fillers excel at immediate physical volume restoration, but they do not alter cellular function or promote long-term biological repair. Hydroxyapatite and poly-L-lactic acid act as biostimulators by inducing a controlled foreign-body response; this mechanical stimulation triggers localized fibrosis.

Polynucleotides operate through a different mechanism entirely. They do not rely on foreign-body reactions to stimulate collagen. Instead, they act as genuine cell signaling molecules that supply metabolic raw materials while downregulating systemic inflammation. Their pronounced anti-inflammatory effects make them suitable for compromised, sensitive, or inflamed skin conditions where traditional biostimulators might cause excessive irritation.

By improving cellular repair pathways, accelerating wound healing and tissue repair, and encouraging natural extracellular matrix regeneration, polynucleotides represent a distinct, scientifically validated approach to long-term skin health. As research into nucleic acid therapies advances, their role in regenerative dermatology will likely expand further.